Cidara's COO Sells Shares Amid Strong Stock Performance Shane Ward, COO of Cidara Therapeutics, sold shares worth $36,542 to cover tax obligations. The sale follows a robust 68% stock return over the past year. Analysts remain bullish with price targets between $33 and $46, supported by the company's progress with its CD388 flu prevention drug trials.4